Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 16/20 | 1.00 |
| ▸ | CA12 | O43570 | 15/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | ELANE | P08246 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 7/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7903703 | 0.90 | CA9 (1.00) | CA9CA12ALDH1A1CYP2C19ELANE | |
| SCHEMBL1758371 | 0.89 | CA9 (1.00) | CA9CA12ALDH1A1CYP2C19ELANE | |
| SCHEMBL14560535 | 0.87 | CA9 (0.97) | CA9CA12ALDH1A1CYP2C19ELANE | |
| Hydrogen Sulfide SCHEMBL28848798 | 0.87 | CA9 (0.97) | CA9CA12ALDH1A1CYP2C19ELANE | |
| SCHEMBL29621871 | 0.87 | CA9 (0.97) | CA9CA12ALDH1A1CYP2C19ELANE | |
| SCHEMBL30834902 | 0.86 | CA12 (1.00) | CA9CA12ALDH1A1CYP2C19ELANE | |
| SCHEMBL1101896 | 0.86 | CA12 (1.00) | CA9CA12ALDH1A1CYP2C19ELANE | |
| SCHEMBL27182867 | 0.83 | CA9 (0.70) | CA9CA12ALDH1A1CYP2C19ELANE | |
| SCHEMBL9831972 | 0.83 | CA12 (0.71) | CA9CA12ALDH1A1CYP2C19ELANE | |
| SCHEMBL30872949 | 0.83 | CA12 (0.71) | CA9CA12ALDH1A1CYP2C19ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2852607-B1 | SYNTHESIS OF STEROID SAPONINS | ONCOLOGY RES INTERNATIONAL LIMITED (AU) | 2018-10-24 | — | — | EP | disclosed |
| US-20150105543-A1 | SYNTHESIS | ONCOLOGY RESEARCH INTERNATIONAL LIMITED (AU) | 2015-04-16 | — | — | US | disclosed |
| EP-2852607-A1 | IMPROVED SYNTHESIS | Oncology Research International Limited (AU) | 2015-04-01 | — | — | EP | disclosed |
| EP-2423260-B1 | PROCESS FOR PRODUCING PLASTIC BOTTLE | ADEKA CORP (JP) | 2013-12-04 | — | — | EP | disclosed |
| WO-2013173862-A1 | IMPROVED SYNTHESIS | ONCOLOGY RESEARCH INTERNATIONAL LIMITED (AU) | 2013-11-28 | — | — | WO | disclosed |
| EP-2423260-A1 | PROCESS FOR PRODUCING PLASTIC BOTTLE | Adeka Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105543-A1 | SYNTHESIS | CYP17A1, CYP21A2, CYP11A1 | CA9 1536/4885CA12 610/4885ALDH1A1 3836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.